Abstract
Piroxicam (PRX) was determined in pharmaceutical capsules with differential pulse voltammetry (DPV) in a three electrode system consisting of a pencil graphite electrode (PGE) as working electrode, a Pt wire and a reference electrode of Ag/AgCl/KCl 3 M. An irreversible oxidation peak was observed in Epa c.a. 0.6 V, which correlates to the oxidation of PRX. The coefficient of linear correlation obtained was 0.9946, with limit of detection of 2.1 µM and limit of quantification of 4.7 µM. PGE assays showed good analytical performance compared to high performance liquid chromatography and spectrophotometry, showing the potential to be further developed and employed in quick and simple analyses.
Highlights
Piroxicam (PRX) is an oxicam non-steroidal anti-inflammatory drug (NSAID) widely used as antiinflammatory, analgesic and antipyretic agent
In order to evaluate and ascertain optimal analytical parameters, the differential pulse voltammetry (DPV) assays were performed for PRX in different acetate and phosphate buffer solutions pHs
Voltammetric determination of PRX capsules with EQMs have higher sensitivity than with pencil graphite electrode (PGE)
Summary
Piroxicam (PRX) is an oxicam non-steroidal anti-inflammatory drug (NSAID) widely used as antiinflammatory, analgesic and antipyretic agent. It exerts biological effect through dual cyclooxygenase (COX) inhibition, i.e., inhibition of both COX-1 and COX-2 isoforms (Sangha, Yao, Wolfe, 2005; Rai, Sarkar, Raha, 2005). Given the high prevalence of inflammatory illnesses, NSAIDs therapy is widespread in medicine (Roddy, Choi, 2014; Perkins et al, 2015) These drugs have been stated to exhibit chemo suppressive and chemo protective properties (Sporn, Suh, 2000), which supported their inclusion in the treatment of some cancer types such as colorectal cancer (Schror, 2011). As described in official compendia, methods such as gas, liquid or high performance liquid chromatography (HPLC), as well as spectrophotometric methods are the main indicated approaches to assess NSAIDs in pharmaceutical forms (Anvisa, 2010; USP, 2016)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
